A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients
with Advanced Malignancies
This study is being done to test the good and bad effects of DCC-3014-01-001 in patients with breast cancer, prostate cancer, gastric cancer, ovarian cancer or non-small cell lung cancer.
non-small cell lung cancer (NSCLC)
1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 90
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. 75 days after last dose of study drug, participants will have a follow-up visit.
Knight Clinical Trials Information Line
Deciphera Pharmaceuticals, LLC